Abstract:Abstract Growing evidence indicates that tumor cells exhibit characteristics similar to their lineage progenitor cells. We found that S100 calcium binding protein A10 (S100A10) exhibited an expression pattern similar to that of liver progenitor genes. However, the role of S100A10 in hepatocellular carcinoma (HCC) progression is unclear. Furthermore, extracellular vesicles (EVs) or exosomes are critical mediator of tumorigenesis and metastasis, but the extracellular functions of S100A10, particularly those related to EVs (EV-S100A10), are unknown. In this study, we observed that S100A10 was upregulated at mRNA level in patients’ HCC tumors as compared to the corresponding non-tumorous livers, associated with a copy-number gain. Overexpression of S100A10 was correlated with more aggressive tumor features and poor prognosis. Furthermore, functional assays demonstrated it promoted HCC initiation and progression, including increased sphere forming ability in vitro, enhanced chemoresistance, upregulated liver cancer stemness markers and activated AKT and ERK pathways. In addition, in orthotopic injection mouse model, S100A10 enhanced both the intrahepatic and pulmonary metastasis of HCC xenografts, with upregulated epithelial-mesenchymal transition (EMT) changes. Of significance, we found that S100A10 was present in EVs secreted by HCC cells. Functionally, the EVs secreted by HCC cells promoted the migratory and invasive abilities of recipient HCC cells. Consistent with the oncogenic role of S100A10 in HCC, EVs from S100A10-overexpressing HCC cells enhanced the tumor promoting effects, while the S100A10-depleted HCC cells abrogated the effects, as compared to the vector control group. To further consolidate the tumor promoting role of S100A10-EV, we blocked the effects using neutralizing antibody (NA) by pretreating HCC cells with S100A10 NA together with EV. Indeed, the NA significantly abrogated the stemness and metastatic properties induced by S100A10-EVs both in vitro and in vivo. In addition, the EMT changes and activation of AKT and ERK were also validated in the recipient HCC cells with the S100A10-EV treatment, while they were abolished with the NA treatment. Moreover, we found that S100A10 governed the protein cargos in EVs and mediated the binding of MMP2, fibronectin and EGF to EV membranes through physical binding with integrin αV to promote the motility of recipient cells. Of note, we observed a simultaneous change of p-EGFR, indicating potential activation of AKT and ERK induced by EGFR. On the other hand, we found the plasma EV-S100A10 level was relatively higher in HCC patients than healthy donors. Collectively, the data showed that S100A10 could be transferred among cells through EVs and activated signaling pathways to facilitate metastasis. Targeting S100A10 may be a potential therapeutic strategy for HCC. Citation Format: Lu TIAN, Xia WANG, Jingyi LU, HongYang Huang, Goofy Yu-Man Tsui, Karen Man-Fong Sze, Tan-To Cheung, Irene Oi-Lin NG. S100A10 promotes HCC development and progression via transfer in extracellular vesicles and regulating their protein cargos. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3985.

Tumour extracellular vesicle‐derived Complement Factor H promotes tumorigenesis and metastasis by inhibiting complement‐dependent cytotoxicity of tumour cells

Small Extracellular Vesicle‐Derived vWF Induces a Positive Feedback Loop between Tumor and Endothelial Cells to Promote Angiogenesis and Metastasis in Hepatocellular Carcinoma

Extracellular vesicles in the HCC microenvironment: Implications for therapy and biomarkers

Role of extracellular vesicle-associated proteins in the progression, diagnosis, and treatment of hepatocellular carcinoma

S100A10 promotes HCC development and progression via transfer in extracellular vesicles and regulating their protein cargos

HCC-derived exosomes elicit HCC progression and recurrence by epithelial-mesenchymal transition through MAPK/ERK signalling pathway

Abstract 3985: S100A10 promotes HCC development and progression via transfer in extracellular vesicles and regulating their protein cargos

Circulating tumor cells shielded with extracellular vesicle-derived CD45 evade T cell attack to enable metastasis

Interplay among extracellular vesicles, cancer stemness and immune regulation in driving hepatocellular carcinoma progression

Bone Lesion‐Derived Extracellular Vesicles Fuel Prometastatic Cascades in Hepatocellular Carcinoma by Transferring ALKBH5‐Targeting miR‐3190‐5p

Complement factor H: a novel innate immune checkpoint in cancer immunotherapy

Cancer cell-derived extracellular vesicles activate hepatic stellate cells in colorectal cancer

Tumour extracellular vesicles and particles induce liver metabolic dysfunction

Cancer associated-fibroblast-derived exosomes in cancer progression

Cancer Cell Derived Small Extracellular Vesicles Contribute to Recipient Cell Metastasis Through Promoting HGF/c-Met Pathway,

Extracellular Vesicles and Hepatocellular Carcinoma: Opportunities and Challenges

Extracellular vesicular lncRNA FAL1 promotes hepatocellular carcinoma cell proliferation and invasion by inducing macrophage M2 polarization

Cathelicidin Antimicrobial Peptide Acts as a Tumor Suppressor in Hepatocellular Carcinoma

Vascular Endothelial Cells Facilitated HCC Invasion and Metastasis Through the Akt and NF-κB Pathways Induced by Paracrine Cytokines

Extracellular vesicles promotes liver metastasis of lung cancer by ALAHM increasing hepatocellular secretion of HGF

Therapeutic potential of tLyp-1-EV-shCTCF in inhibiting liver cancer stem cell self-renewal and immune escape via SALL3 modulation in hepatocellular carcinoma